| Dr Hilton M Hudson Ii, MD | |
|
3500 Franciscan Way Ste 400, Michigan City, IN 46360-0021 | |
| (219) 878-8200 | |
| (219) 877-8331 |
| Full Name | Dr Hilton M Hudson Ii |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 37 Years |
| Location | 3500 Franciscan Way Ste 400, Michigan City, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689614828 | NPI | - | NPPES |
| 000001005945 | Other | IN | ANTHEM PROVIDER NUMBER |
| 01618941 | Other | IL | BC/BS OF IL |
| 036089208 | Medicaid | IL | |
| 200441260 | Medicaid | IN | |
| 211578003 | Other | IL | MEDICARE PROVIDER |
| Facility Name | Location | Facility Type |
|---|---|---|
| At Home Healthcare | Beloit, WI | Home health agency |
| Beloit Health System | Beloit, WI | Hospital |
| Franciscan Health Olympia Fields & Chicago Heights | Olympia fields, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Physician Network | 3072790682 | 989 |
| Specialty Physicians Of Illinois Llc | 4183529456 | 105 |
| Beloit Health System Inc | 8224947858 | 110 |
News Archive
Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study
Researchers at Cornell University have shown for the first time that it is possible to reduce ageist attitudes, prejudices and stereotypes through education and intergenerational contact.
Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.
Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).
› Verified 2 days ago
| Entity Name | Arnett Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164490843 PECOS PAC ID: 0749184380 Enrollment ID: O20031125000119 |
News Archive
Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study
Researchers at Cornell University have shown for the first time that it is possible to reduce ageist attitudes, prejudices and stereotypes through education and intergenerational contact.
Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.
Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).
› Verified 2 days ago
| Entity Name | Indiana University Health Care Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902032832 PECOS PAC ID: 5799755864 Enrollment ID: O20040727000955 |
News Archive
Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study
Researchers at Cornell University have shown for the first time that it is possible to reduce ageist attitudes, prejudices and stereotypes through education and intergenerational contact.
Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.
Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).
› Verified 2 days ago
| Entity Name | The Methodist Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720290588 PECOS PAC ID: 9638063894 Enrollment ID: O20080805000003 |
News Archive
Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study
Researchers at Cornell University have shown for the first time that it is possible to reduce ageist attitudes, prejudices and stereotypes through education and intergenerational contact.
Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.
Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).
› Verified 2 days ago
| Entity Name | Franciscan Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225327984 PECOS PAC ID: 3072790682 Enrollment ID: O20110608000486 |
News Archive
Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study
Researchers at Cornell University have shown for the first time that it is possible to reduce ageist attitudes, prejudices and stereotypes through education and intergenerational contact.
Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.
Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hilton M Hudson Ii, MD Po Box 781076, Detroit, MI 48278-1076 Ph: (317) 528-4800 | Dr Hilton M Hudson Ii, MD 3500 Franciscan Way Ste 400, Michigan City, IN 46360-0021 Ph: (219) 878-8200 |
News Archive
Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study
Researchers at Cornell University have shown for the first time that it is possible to reduce ageist attitudes, prejudices and stereotypes through education and intergenerational contact.
Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.
Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).
› Verified 2 days ago